| US 7,514,417 B2 | ||
| A1 adenosine receptor agonists | ||
| Elfatih Elzein, Fremont, Calif. (US); Rao Kalla, Sunnyvale, Calif. (US); Thao Perry, San Jose, Calif. (US); Jeff Zablocki, Mountain View, Calif. (US); and Xiaofen Li, Mountain View, Calif. (US) | ||
| Assigned to CV Therapeutics, Inc., Palo Alto, Calif. (US) | ||
| Filed on May 19, 2006, as Appl. No. 11/437,242. | ||
| Claims priority of provisional application 60/683505, filed on May 19, 2005. | ||
| Prior Publication US 2006/0281705 A1, Dec. 14, 2006 | ||
| Int. Cl. A01N 43/04 (2006.01); A61K 31/70 (2006.01) | ||
| U.S. Cl. 514—46 [514/45; 514/47; 514/263.2; 536/27.3; 536/27.6; 536/27.61; 544/277] | 23 Claims |
1. A method for treating a disease or condition that can be treated with a partial or full A1 adenosine receptor agonist, the method comprising the administration to a mammal in need thereof of a therapeutically effective
amount of a compound that is a partial or full A1 adenosine receptor agonist, said compound having the structure of Formula I:
 R1 is hydroxymethyl, —C(O)OR6, or —C(O)NHR6, in which R6 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted
aryl, or optionally substituted heteroaryl;
R2 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted
aryl, or optionally substituted heteroaryl;
R3, R4, and R5 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aryl,
optionally substituted heteroaryl, —CO2H, —SO3H, —C(O)OR6, —CH(OH)R6, or —C(O)NR6R7, wherein R7 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted
aryl, or optionally substituted heteroaryl,
or a salt, hydrate, or pharmaceutically acceptable ester thereof;
wherein the disease or condition is chosen from atrial fibrillation, atrial flutter, congestive heart failure, epilepsy, stroke,
diabetes, obesity, ischemia, stable angina, unstable angina, myocardial infarction, cardiac transplant, hyperlipidemia, hypertriglyceridemia,
and metabolic syndrome.
|